Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Gille

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Journal of Clinical Pharmacology|October 15, 2013
A multiple ascending dose study of CSL112, an infused formulation of ApoA-IRachael Easton, Andreas Gille, Denise D'Andrea, et al.
Molecular Pharmacology|June 13, 2006
Broad specificity of mammalian adenylyl cyclase for interaction with 2',3'-substituted purine- and pyrimidine nucleotide inhibitorsTung-Chung Mou, Andreas Gille, Srividya Suryanarayana, et al.
Biochemical Pharmacology|November 8, 2005
Differential interactions of G-proteins and adenylyl cyclase with nucleoside 5'-triphosphates, nucleoside 5'-[gamma-thio]triphosphates and nucleoside 5'-[beta,gamma-imido]triphosphatesAndreas Gille, Jianxin Guo, Tung-Chung Mou, et al.
Journal of Immunological Methods|January 1, 2023
A method for detection of anti-drug antibodies to a biotherapeutic (CSL112) with endogenous counterpart (apolipoprotein A-I) using a novel sample pre-treatment electrochemiluminescence assayRoslyn Davis, Elena Velkoska, Helen McCallum, et al.
Nature Medicine|January 13, 2015
Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetesCong Tang, Kashan Ahmed, Andreas Gille, et al.
Journal of Clinical Pharmacology|November 20, 2018
Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux CapacityAndreas Gille, Danielle Duffy, Michael A Tortorici, et al.
The Journal of Biological Chemistry|February 26, 2004
Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotidesAndreas Gille, Gerald H Lushington, Tung-Chung Mou, et al.
Biochemical Pharmacology|May 19, 2009
Differential interactions of the catalytic subunits of adenylyl cyclase with forskolin analogsCibele Pinto, Melanie Hübner, Andreas Gille, et al.
Cell Metabolism|April 9, 2010
An autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81Kashan Ahmed, Sorin Tunaru, Cong Tang, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 23, 2013
Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol effluxSvetlana Diditchenko, Andreas Gille, Ingo Pragst, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Journal of Clinical Pharmacology|October 15, 2013
A multiple ascending dose study of CSL112, an infused formulation of ApoA-IRachael Easton, Andreas Gille, Denise D'Andrea, et al.
Molecular Pharmacology|June 13, 2006
Broad specificity of mammalian adenylyl cyclase for interaction with 2',3'-substituted purine- and pyrimidine nucleotide inhibitorsTung-Chung Mou, Andreas Gille, Srividya Suryanarayana, et al.
Biochemical Pharmacology|November 8, 2005
Differential interactions of G-proteins and adenylyl cyclase with nucleoside 5'-triphosphates, nucleoside 5'-[gamma-thio]triphosphates and nucleoside 5'-[beta,gamma-imido]triphosphatesAndreas Gille, Jianxin Guo, Tung-Chung Mou, et al.
Journal of Immunological Methods|January 1, 2023
A method for detection of anti-drug antibodies to a biotherapeutic (CSL112) with endogenous counterpart (apolipoprotein A-I) using a novel sample pre-treatment electrochemiluminescence assayRoslyn Davis, Elena Velkoska, Helen McCallum, et al.
Nature Medicine|January 13, 2015
Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetesCong Tang, Kashan Ahmed, Andreas Gille, et al.
Journal of Clinical Pharmacology|November 20, 2018
Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux CapacityAndreas Gille, Danielle Duffy, Michael A Tortorici, et al.
The Journal of Biological Chemistry|February 26, 2004
Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotidesAndreas Gille, Gerald H Lushington, Tung-Chung Mou, et al.
Biochemical Pharmacology|May 19, 2009
Differential interactions of the catalytic subunits of adenylyl cyclase with forskolin analogsCibele Pinto, Melanie Hübner, Andreas Gille, et al.
Cell Metabolism|April 9, 2010
An autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81Kashan Ahmed, Sorin Tunaru, Cong Tang, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 23, 2013
Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol effluxSvetlana Diditchenko, Andreas Gille, Ingo Pragst, et al.
Pageof 5